Markers of Epstein-Barr virus and Human Herpesvirus-6 infection and multiple sclerosis clinical progression.

Antibodies, Viral Epstein-Barr Virus Infections / complications Herpesvirus 4, Human / genetics Herpesvirus 6, Human / physiology Humans Infectious Mononucleosis / complications Multiple Sclerosis / diagnosis
Conversion Epstein-Barr virus First demyelinating event Human herpesvirus-6 Relapse multiple sclerosis

Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 13 08 2021
revised: 09 01 2022
accepted: 23 01 2022
pubmed: 9 2 2022
medline: 8 4 2022
entrez: 8 2 2022
Statut: ppublish

Résumé

Infections with Epstein-Barr virus (EBV) and human herpesvirus-6 (HHV-6) have been implicated in multiple sclerosis (MS) onset but little work has studied their relationships in early disease. Evaluate associations between markers of EBV and HHV-6 infection/reactivation and MS conversion, relapse and EDSS/MSSS amongst 205 CIS participants with EBV/HHV-6 data followed over 5 years. Baseline serological and viral load measures of EBV and HHV-6 exposure/reactivation were measured and infectious mononucleosis (IM) history recorded. Conversion to MS and relapses were assessed annually, and EDSS/MSSS measured at 5-year review. Determinants of MS conversion and relapse assessed by Cox regression, and disability progression by linear regression. IM history showed a strong positive trend with higher relapse risk (aHR=1.45,95%CI=0.97-2.16) but was not associated with MS conversion (aHR=0.92,95%CI=0.57-1.48). Anti-HHV-6 IgG titre>40 also showed strong positive trends with higher relapse (aHR=1.61,95%CI=0.99-2.63) and MS conversion risks (aHR=1.48,95%CI=0.89-2.46). Anti-HHV-6 IgG titre≥640 was significantly associated with higher MSSS (0.15(95%CI=0.00,0.30) and also showed a strong positive trend with higher EDSS 0.10(95%CI=-0.02,0.21). HHV-6 DNA detection showed strong positive trends with 83%(95%CI=-6-357) and 77%(95%CI=-4-328) higher MS conversion and relapse risk. Anti-EBV-EA-D IgG titre was associated with a lower annualised disability progression by EDSS (p Overall, our data provides evidence that higher HHV-6 IgG was associated with increased risk of MS conversion and relapse but of borderline significance, and greater annualised disability progression, while that for EBV was more limited.

Sections du résumé

BACKGROUND BACKGROUND
Infections with Epstein-Barr virus (EBV) and human herpesvirus-6 (HHV-6) have been implicated in multiple sclerosis (MS) onset but little work has studied their relationships in early disease.
OBJECTIVE OBJECTIVE
Evaluate associations between markers of EBV and HHV-6 infection/reactivation and MS conversion, relapse and EDSS/MSSS amongst 205 CIS participants with EBV/HHV-6 data followed over 5 years.
METHOD METHODS
Baseline serological and viral load measures of EBV and HHV-6 exposure/reactivation were measured and infectious mononucleosis (IM) history recorded. Conversion to MS and relapses were assessed annually, and EDSS/MSSS measured at 5-year review. Determinants of MS conversion and relapse assessed by Cox regression, and disability progression by linear regression.
RESULTS RESULTS
IM history showed a strong positive trend with higher relapse risk (aHR=1.45,95%CI=0.97-2.16) but was not associated with MS conversion (aHR=0.92,95%CI=0.57-1.48). Anti-HHV-6 IgG titre>40 also showed strong positive trends with higher relapse (aHR=1.61,95%CI=0.99-2.63) and MS conversion risks (aHR=1.48,95%CI=0.89-2.46). Anti-HHV-6 IgG titre≥640 was significantly associated with higher MSSS (0.15(95%CI=0.00,0.30) and also showed a strong positive trend with higher EDSS 0.10(95%CI=-0.02,0.21). HHV-6 DNA detection showed strong positive trends with 83%(95%CI=-6-357) and 77%(95%CI=-4-328) higher MS conversion and relapse risk. Anti-EBV-EA-D IgG titre was associated with a lower annualised disability progression by EDSS (p
CONCLUSION CONCLUSIONS
Overall, our data provides evidence that higher HHV-6 IgG was associated with increased risk of MS conversion and relapse but of borderline significance, and greater annualised disability progression, while that for EBV was more limited.

Identifiants

DOI: 10.1016/j.msard.2022.103561 PMID: 35131728
pubmed: 35131728
pii: S2211-0348(22)00076-1
doi: 10.1016/j.msard.2022.103561
pii:
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103561

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Chunrong Tao (C)

Multiple Sclerosis Flagship, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia; Department of Neurology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

Steve Simpson-Yap (S)

Multiple Sclerosis Flagship, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia; Neuroepidemiology Unit, Melbourne School of Population & Global Health, The University of Melbourne, Carlton, Australia. Electronic address: steve.simpsonyap@unimelb.edu.au.

Bruce Taylor (B)

Multiple Sclerosis Flagship, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia.

Leigh Blizzard (L)

Multiple Sclerosis Flagship, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia.

Robyn Lucas (R)

National Centre for Epidemiology and Population Health, Research School of Population Health, Australian National University, Canberra, Australia; Centre for Ophthalmology and Visual Science, University of Western Australia, Perth, Australia.

Anne-Louise Ponsonby (AL)

Centre for Ophthalmology and Visual Science, University of Western Australia, Perth, Australia; The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Australia; Murdoch Children's Research Institute, The University of Melbourne, Melbourne, Australia.

Simon Broadley (S)

School of Medicine, Gold Coast Campus, Griffith University QLD, Australia.

Ingrid van der Mei (I)

Multiple Sclerosis Flagship, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia. Electronic address: ingrid.vandermei@utas.edu.au.
A full list of members is provided in the Acknowledgments.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Markers of Epstein-Barr virus and Human...
questionsmedicales.fr › Infection › Maladies virales › Infections à virus oncogènes › Infections à virus Epstein-Barr › Markers of Epstein-Barr virus and Human...
questionsmedicales.fr › Virus › Virus oncogènes › Virus tumoraux à ADN › Gammaherpesvirinae › Lymphocryptovirus › Herpèsvirus humain de type 4 › Markers of Epstein-Barr virus and Human...
questionsmedicales.fr › Virus › Virus à ADN › Herpesviridae › Betaherpesvirinae › Roseolovirus › Herpèsvirus humain de type 6 › Markers of Epstein-Barr virus and Human...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Markers of Epstein-Barr virus and Human...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Mononucléose infectieuse › Markers of Epstein-Barr virus and Human...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Maladies auto-immunes du système nerveux › Maladies démyélinisantes auto-immunes du SNC › Sclérose en plaques › Markers of Epstein-Barr virus and Human...